Fetal-onset malignant rhabdoid tumor: a case report.
Ex-utero intrapartum treatment
Fetal diagnosis
Fetal onset
Malignant rhabdoid tumor
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
20 Jul 2022
20 Jul 2022
Historique:
received:
04
05
2022
accepted:
20
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
A fetal-onset cervical mass may cause postnatal airway obstruction, and ex utero intrapartum treatment (EXIT) to secure the airway while maintaining fetal-placental circulation may be life-saving. Malignant rhabdoid tumors (MRT) are highly aggressive tumors, and when they develop in utero, the prognosis is even worse, with almost no reports of survival beyond the neonatal period. Herein, we report a case of a primary cervical MRT and describe our treatment using EXIT for securing the airway, wherein the infant's life was saved. A 40-year-old Japanese woman with no relevant medical or surgical history was diagnosed with a fetal left cervical mass and polyhydramnios during the third trimester. Fetal magnetic resonance imaging indicated the possibility of postnatal airway obstruction, and delivery using EXIT was planned. The infant was delivered by a planned cesarean section at 39 weeks and 5 days gestation, and tracheostomy was performed using EXIT. Postnatal contrast-enhanced computed tomography revealed suspected metastatic lesions in the subcutaneous tissue, lungs, and thymus, in addition to the mass in the left cervical region. MRT was diagnosed by biopsy of a subcutaneous mass in the left thigh, and chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide was initiated. The tumors regressed, and the infant was successfully weaned from artificial ventilation. After discharge from the hospital, she had a recurrent cervical mass and intracranial metastasis, and radiotherapy was initiated. In our case, fetal diagnosis enabled advance planning of delivery using EXIT, thus saving the infant's life. The use of chemotherapy for MRT, which has a poor prognosis, allowed tumor regression and enabled the infant to survive beyond the neonatal period.
Sections du résumé
BACKGROUND
BACKGROUND
A fetal-onset cervical mass may cause postnatal airway obstruction, and ex utero intrapartum treatment (EXIT) to secure the airway while maintaining fetal-placental circulation may be life-saving. Malignant rhabdoid tumors (MRT) are highly aggressive tumors, and when they develop in utero, the prognosis is even worse, with almost no reports of survival beyond the neonatal period. Herein, we report a case of a primary cervical MRT and describe our treatment using EXIT for securing the airway, wherein the infant's life was saved.
CASE PRESENTATION
METHODS
A 40-year-old Japanese woman with no relevant medical or surgical history was diagnosed with a fetal left cervical mass and polyhydramnios during the third trimester. Fetal magnetic resonance imaging indicated the possibility of postnatal airway obstruction, and delivery using EXIT was planned. The infant was delivered by a planned cesarean section at 39 weeks and 5 days gestation, and tracheostomy was performed using EXIT. Postnatal contrast-enhanced computed tomography revealed suspected metastatic lesions in the subcutaneous tissue, lungs, and thymus, in addition to the mass in the left cervical region. MRT was diagnosed by biopsy of a subcutaneous mass in the left thigh, and chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide was initiated. The tumors regressed, and the infant was successfully weaned from artificial ventilation. After discharge from the hospital, she had a recurrent cervical mass and intracranial metastasis, and radiotherapy was initiated.
CONCLUSIONS
CONCLUSIONS
In our case, fetal diagnosis enabled advance planning of delivery using EXIT, thus saving the infant's life. The use of chemotherapy for MRT, which has a poor prognosis, allowed tumor regression and enabled the infant to survive beyond the neonatal period.
Identifiants
pubmed: 35854325
doi: 10.1186/s13256-022-03503-7
pii: 10.1186/s13256-022-03503-7
pmc: PMC9297601
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
282Informations de copyright
© 2022. The Author(s).
Références
J Pediatr Surg. 2015 Feb;50(2):311-4
pubmed: 25638626
Prenat Diagn. 2013 Nov;33(11):1080-7
pubmed: 23868540
J Perinatol. 2008 Sep;28(9):649-51
pubmed: 18756277
Anesth Analg. 2016 Aug;123(2):411-7
pubmed: 27258076
Lancet Oncol. 2013 Jul;14(8):e329-36
pubmed: 23816299
Case Rep Obstet Gynecol. 2018 Jan 31;2018:6073204
pubmed: 29670784
Mod Pathol. 2005 Jul;18(7):951-8
pubmed: 15761491
BMJ Case Rep. 2018 Apr 13;2018:
pubmed: 29654100
J Pediatr Surg. 2010 Mar;45(3):619-26
pubmed: 20223330
Eur J Cancer. 2016 Jun;60:69-82
pubmed: 27082136
Nature. 1998 Jul 9;394(6689):203-6
pubmed: 9671307
Cancer. 2007 Nov 1;110(9):2061-6
pubmed: 17828773
J Pediatr Surg. 2002 Mar;37(3):418-26
pubmed: 11877660
Oncologist. 2019 Jul;24(7):e551-e558
pubmed: 30914466